CDI may complicate the course of IBD, however the presentation may not be typical. Therefore, all patients with worsening gastrointestinal symptoms should be evaluated for both CDI and IBD exacerbation. Providers should consider FMT for all patients with recurrent CDI as well as escalation of immuno …

Clostridioides difficile is the leading cause of antibiotic-associated diarrhea but can also result in more serious, life-threatening conditions. The incidence of C. difficile infections in hospitals is increasing, both in frequency and severity, and antibiotic-resistant C. difficil …

Clostridioides difficile is an anaerobic pathogen that causes significant morbidity and mortality. Understanding the mechanisms of colonization resistance against C. difficile is important for elucidating the mechanisms by which C. difficile is able to colonize the gut after ant …

We treated 46 patients with multiple recurrent Clostridioides difficile infections (mrCDI) using a tapered-pulsed (T-P) fidaxomicin regimen, the majority of whom failed prior T-P vancomycin treatment. Sustained clinical response rates at 30 and 90 days were 74% (34/46) and 61% (28/46). T-P fidaxomic …

Although clostridioides difficile is the leading cause of health care-associated infection in the United States, there are currently only 2 antibiotics available for its treatment: vancomycin and fidaxomicin.

Rates of serious clinical complications of Clostridioides difficile infection rose as the number of recurrent infections increased, underscoring the importance of advancing new treatments to prevent recurrence of the disease, a recent study in SAGE Open Medicine found.

Implications for prescribing vancomycin or fidaxomicin to treat C. difficile infections.  

A discussion on fidaxomicin as treatment for C. difficile infections and clinician feedback on current challenges that impact its use in clinical practice.  

Important factors to consider when selecting an appropriate therapy to treat C. difficile.

Missed diagnosis resulted in delays in initiation of therapy and hospital re-admissions.

Implications regarding how to properly treat patients with C. difficile infections based on data that have emerged since clinical practice guidelines were last updated.

Patients with 3 or more C diff recurrences also had the highest health care resources utilization and total, all-cause, direct medical costs.

A panel of clinicians recognize the challenges associated with screening patients for the C. difficile infection and highlight factors that should prompt someone for an evaluation.  

Types of testing algorithms used in clinical practice to help clarify a diagnosis of C difficile infection.  

Important things to understand about diagnosing C. difficile and recommendations for properly differentiating the condition from other diseases when working-up a patient.

Revised clinical practice guidelines for Clostridioides difficile that were published in February 2018 led to immediate, significant increases in oral vancomycin and fidaxomicin use in the United States, as well as a significant decrease in oral metronidazole use, according to findings published in Clinical Infectious Diseases. “Shortly before this study, the Infectious Diseases Society of

A discussion regarding the increasing frequency of C. difficile recurrence and its effects on patients and the health care system.

Sources of transmission and challenges that impact the management of community-onset C. difficile.  

The bowel resting strategy might reduce switching from metronidazole to vancomycin among patients with Clostridioides difficile infection, but it might not reduce mortality or recurrence, a new study found.

What health care providers need to know about the 2 strains of C. difficile, including types of patients impacted and typical outcomes.

It’s possible that C diff could be a marker for frailty in geriatric patients.

Understanding the burden of C. difficile across the United States, panelists explore common risk factors associated with the condition and discuss the different ways it can manifest in patients.

An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.

Peer Exchange Coming Soon